A Study to Assess Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization in Chinese Participants Receiving Upadacitinib for Atopic Dermatitis (AD) Through Chart Review
- Conditions
- Atopic Dermatitis (AD)
- Registration Number
- NCT06503536
- Lead Sponsor
- AbbVie
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria:<br><br> - Participants with at least one primary diagnosis of atopic dermatitis with ICD-10<br> code of L20.900 [atopic dermatitis, unspecified] or physician-confirmed atopic<br> dermatitis documentation within the study period<br><br> - Participants with at least one documented health record of upadacitinib prescription<br> that has a primary diagnosis of atopic dermatitis within the study period<br><br> - Participants with at least one atopic dermatitis severity measures (i.e., EASI) in<br> the follow-up period including up to 6 months after the index date<br><br>Exclusion Criteria:<br><br>• Participants who did not fulfill the inclusion criteria will be excluded
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Number of participants who achieve a composite endpoint post-index score of Eczema Area and Severity Index (EASI) < =7;Number of participants who achieve a composite endpoint post-index score of Investigator's Global Assessment (IGA) × Body Surface Area (BSA) < = 30
- Secondary Outcome Measures
Name Time Method